218 related articles for article (PubMed ID: 18300041)
1. Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.
Zaki Mel S; Auf FA; Ghawalby NA; Saddal NM
Immunol Invest; 2008; 37(2):163-70. PubMed ID: 18300041
[TBL] [Abstract][Full Text] [Related]
2. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.
Bortolami M; Kotsafti A; Cardin R; Farinati F
J Viral Hepat; 2008 Jul; 15(7):515-22. PubMed ID: 18331250
[TBL] [Abstract][Full Text] [Related]
3. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C.
Panasiuk A; Parfieniuk A; Zak J; Flisiak R
Liver Int; 2010 Mar; 30(3):472-8. PubMed ID: 19919570
[TBL] [Abstract][Full Text] [Related]
4. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA
J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
[TBL] [Abstract][Full Text] [Related]
6. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
7. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection.
Macias J; Japón MA; Sáez C; Palacios RB; Mira JA; García-García JA; Merchante N; Vergara S; Lozano F; Gómez-Mateos J; Pineda JA
J Infect Dis; 2005 Nov; 192(9):1566-76. PubMed ID: 16206071
[TBL] [Abstract][Full Text] [Related]
8. Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens.
Caronia S; McGarvey MJ; Goldin RD; Foster GR
J Viral Hepat; 2004 Nov; 11(6):511-8. PubMed ID: 15500551
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the fas system in hepatitis C virus recurrence after liver transplantation.
Crespo J; Rivero M; Mayorga M; Fabrega E; Casafont F; Gomez-Fleitas M; Pons-Romero F
Liver Transpl; 2000 Sep; 6(5):562-9. PubMed ID: 10980054
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of ssDNA in liver tissue and its correlation with sFas and sFasL in serum of patients infected with HBV, HCV, HCV and HIV.
Łapinski TW; Wiercińska-Drapało A; Panasiuk A; Kovalchuk O
Adv Med Sci; 2007; 52():109-13. PubMed ID: 18217400
[TBL] [Abstract][Full Text] [Related]
11. Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus.
Rubbia-Brandt L; Taylor S; Gindre P; Quadri R; Abid K; Spahr L; Negro F
J Pathol; 2002 Aug; 197(5):617-23. PubMed ID: 12210081
[TBL] [Abstract][Full Text] [Related]
12. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities.
Fiore G; Piazzolla G; Galetta V; Caccetta L; Schiraldi O; Antonaci S
Microbios; 1999; 97(386):29-38. PubMed ID: 10413866
[TBL] [Abstract][Full Text] [Related]
13. Analysis of apoptotic markers Fas/FasL (CD95/CD95L) expression on the lymphocytes in patients with acute coronary syndrome.
Bossowska A; Bossowski A; Galar B
Kardiol Pol; 2007 Aug; 65(8):883-9; discussion 890-2. PubMed ID: 17853317
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C.
Wedemeyer I; Bechmann LP; Odenthal M; Jochum C; Marquitan G; Drebber U; Gerken G; Gieseler RK; Dienes HP; Canbay A
J Hepatol; 2009 Jan; 50(1):140-9. PubMed ID: 19019483
[TBL] [Abstract][Full Text] [Related]
15. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
[TBL] [Abstract][Full Text] [Related]
16. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
17. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure.
Ryo K; Kamogawa Y; Ikeda I; Yamauchi K; Yonehara S; Nagata S; Hayashi N
Am J Gastroenterol; 2000 Aug; 95(8):2047-55. PubMed ID: 10950056
[TBL] [Abstract][Full Text] [Related]
18. Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis--ANRS HC EP07 study.
Bonilla N; Barget N; Andrieu M; Roulot D; Letoumelin P; Grando V; Trinchet JC; Ganne-Carrié N; Beaugrand M; Deny P; Choppin J; Guillet J; Ziol M
J Viral Hepat; 2006 Jul; 13(7):474-81. PubMed ID: 16792541
[TBL] [Abstract][Full Text] [Related]
19. The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C.
Aguilar-Reina J; Ruiz-Ferrer M; Pizarro MA; Antiñolo G
J Viral Hepat; 2005 Nov; 12(6):568-73. PubMed ID: 16255757
[TBL] [Abstract][Full Text] [Related]
20. Balanced regulation of mRNA production for Fas and Fas ligand in lymphocytes from centenarians: how the immune system starts its second century.
Pinti M; Troiano L; Nasi M; Bellodi C; Ferraresi R; Mussi C; Salvioli G; Cossarizza A
Circulation; 2004 Nov; 110(19):3108-14. PubMed ID: 15505087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
